On Wednesday, Pharmaceutical giant Pfizer Inc signed a deal with German biotech firm BioNTech SE to supply experimental coronavirus vaccines in Canada.
In a joint statement, both the companies said, “Deliveries of the BNT162 mRNA-based vaccine candidate are planned over the course of 2021, subject to clinical success and Health Canada approval”. However, the financial details of the deal were not disclosed by them.
At present, about 19 COVID vaccines globally have reached the stage of human clinical trials.